Experts have urged the Philippine government to expedite the approval of a new-generation of dengue vaccine, amid the rising ...

The US Food and Drug Administration (FDA) has approved Swiss drugmaker Ferring ... (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated ...

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. | A second patient has ...

Ocugen has a valuable IP portfolio, which should give it funding options. OCGN’s cash runway remains the main risk. Check out ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

Despite longstanding reliance on sputum smear microscopy, culture methods, and chest X-rays, conventional TB diagnostics ...

Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an ...

In April 2025, the FDA approved Zevaskyn™ (prademagene zamikeracel or pz-cel ... The copy of the gene is added using a genetically modified herpes simplex virus type 1 (HSV-1) vector. Dosing depends ...

Dr Nittaya Phanuphak is the Executive Director of Institute for HIV Research and Innovation (IHRI), Governing Council member of International AIDS Society (IAS), and Convener of 2nd Asia Pacific ...

For the second time, a person with DMD has died of acute liver failure after being treated with the one-time gene therapy Elevidys.